Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice
Brief intro:
- Author: Jianxiong Zeng, Xiaochun Xie, Xiao-Li Feng, Ling Xu,Jian-Bao Han, Dandan Yu, Qing-Cui Zou, Qianjin Liu, Xiaohong Li, Guanqin Ma, Ming-Hua Li, and Yong-Gang Yao
- Journal: EBioMedicine
- Doi: https://www.doi.org/10.1016/j.ebiom.2021.103803
- Publication Date: 2021 Dec 31
Products/Services used in the paper
Quotation shows PackGene:For AAV-hACE2 infection in mice, C57BL/6J (n = 5) and Nlrp3-KO (n = 5) mice were intranasally incubated with hACE2-expressing AAV (AAV-hACE2) (PackGene Biotech) at a total of 40 ml containing 4 x10^12 viral genome copies (GC) (20 ml per nostril).
Research Field:Covid-related
Animal or cell line strain:C57BL/6J (n = 5) and Nlrp3-KO (n = 5) mice
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
